Technology
Health
Pharmaceutical

Ritter Pharmaceuticals

$1.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RTTR and other stocks, options, ETFs, and crypto commission-free!

About

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. Read More The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Employees
9
Headquarters
Los Angeles, California
Founded
2004
Market Cap
6.02M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
213.20K
High Today
$1.15
Low Today
$1.03
Open Price
$1.14
Volume
219.24K
52 Week High
$4.00
52 Week Low
$0.47

Collections

Technology
Health
Pharmaceutical
2015 IPO
US
North America

News

Markets InsiderMar 5

Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), a condition afflicting more than 40 million people in ...

1,920
MarketBeatFeb 15

Stock Price, News, & Analysis for Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose...

100

Earnings

-$0.94
-$0.64
-$0.35
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.94 per share
Actual
Expected Mar 22, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.